Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Actress Melanie Watson Bernhardt, known for her role on Diff'rent Strokes, passed away at 57. Despite living with ...

Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's Anatomy." Or maybe the words "osteogenesis imperfecta," or "OI," don't ...

Osteogenesis imperfecta (OI) is a heterogeneous group of genetic disorders that affect connective tissue integrity. The hallmark of OI is bone fragility, although other manifestations, which include ...

Mutations in the genes COL1A1, COL1A2, CRTAP, and P3h2 result in OI. In most cases, the inheritance pattern is autosomal dominant and, in some cases, it could also be autosomal recessive. The gene ...

A new study led by Baylor College of Medicine identifies an underlying mechanism of pathogenesis for osteogenesis imperfecta (OI) in human bone. The report, published in the Journal of Clinical ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...

What Is Brittle Bone Disease? Brittle bone disease, also called osteogenesis imperfecta, is a genetic connective tissue disorder that is preset at birth and lasts for life. It causes fragile bones ...